ESC 22 Late-breaker Discussion: The ADVOR Trial

Watch on Radcliffe Cardiology: www.cfrjournal...
Late-breaker host, Dr Harriette Van Spall ((McMaster University, CA) sat down with the principal investigator of the ADVOR trial, Prof Wilfried Mullens (Hospital Oost-Limburg (ZOL), BE) to talk about the trial design and practical consideration in light of the new data.
ADVOR, a multi-centre, randomized, double-blind clinical trial assessed the diuretic effects of acetazolamide (Diamox®) in patients with decompensated heart failure with at least one clinical sign of volume overload.
Patients (519) in this trial were randomised into two groups. Patients in the first group received standard care with high-dose loop diuretics and a placebo. The second group of patients received high-dose loop diuretics with acetazolamide.
The primary outcome measure was treatment success, secondary outcome measures included mortality, hospital readmission, length of hospital stay at 3 months and EuroQoL five dimensions questionnaire (EQ-5D).
Recorded on-site ESC Congress 22, Barcelona.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

[@RaBu-ny2ur]

ADVOR Trial as he suggests only for initial decongestion. For long term effects cannot be extrapolated., might or might not work.

[@dr.ahmedomerlak591]

What about tab if used for post discharge from hospital?
Can be useful in regards of decreasing rehospitalization